

SAD IV
Serum rHuMAb Beta7 Concentration (µg/mL)
1000
100
10
1
0.1
0.01
0
28
56
84
112
140
Time (Day)
0.3 mg/kg IV
1.0 mg/kg IV
3.0 mg/kg IV
10 mg/kg IV

FIG. 1A



SAD IV/SC
Serum rHuMAb Beta7 Concentration (µg/mL)
1000
100
10
1
0.1
0.01
0
28
56
84
112
140
Time (Day)
3.0 mg/kg IV
3 mg/kg SC

FIG. 1B



MAD IV/SC
0.5 mg/kg SC
1.5 mg/kg SC
3.0 mg/kg SC
4.0 mg/kg IV
Serum rHuMAb Beta7 Concentration (µg/mL)
1000
100
10
1
0.1
0
28
56
84
112
140
168
Time (Day)

FIG. 1C



Cohort G (0.5 mg/kg SC)
(Flare D134) V
(Flare D129) W
(Flare D79) X
Y
(P6)
Occupancy Abs Counts (% Predose)
350
300
250
200
150
100
50
0
0
50
100
150
200
Study Day

FIG. 2A



Cohort H (1.5 mg/kg SC)
Occupancy Abs Counts (% Predose)
350
300
250
200
150
100
50
0
AA
BA
(P8)
DA
0
50
100
150
200
Study Day

FIG. 2B



Cohort I (3 mg/kg SC)
Occupancy Abs Counts (% Predose)
350
300
250
200
150
100
50
0
EA
FA
GA
HA
(P9)
0
50
100
150
200
Study Day

FIG. 2C



Cohort J (4 mg/kg IV)
Occupancy Abs Counts (% Predose)
350
300
250
200
150
100
50
0
(Flare D116)
IA
JA
KA
LA
(P10)
MA
0
50
100
150
200
Study Day

FIG. 2D



Cohort G (0.5 mg/kg SC)
Mayo Clinic Score
12
10
8
6
4
2
0
Day 1
Day 43
Day 71
No Steroids
Steroids ≤ 15mg/Day
Steroids ≥ 20mg/Day
Previous antiTNF
Change in UC Conmeds
= Dosing Day

FIG. 3A



Cohort H (1.5 mg/kg SC)
Mayo Clinic Score
12
10
8
6
4
2
0
Day 1
Day 43
Day 71
No Steroids
Steroids ≤ 15mg/Day
Steroids ≥ 20mg/Day
Previous antiTNF
Change in UC Conmeds
= Dosing Day

FIG. 3B



Cohort I (3 mg/kg SC)
Mayo Clinic Score
12
10
8
6
4
2
0
Day 1
Day 43
Day 71
No Steroids
Steroids ≤ 15mg/Day
Steroids ≥ 20mg/Day
Previous antiTNF
Change in UC Conmeds
= Dosing Day

FIG. 3C



Cohort J (4 mg/kg IV)
Mayo Clinic Score
12
10
8
6
4
2
0
Day 1
Day 43
Day 71
No Steroids
Steroids ≤ 15mg/Day
Steroids ≥ 20mg/Day
Previous antiTNF
Change in UC Conmeds
= Dosing Day

FIG. 3D



Placebo
Mayo Clinic Score
12
10
8
6
4
2
0
Day 1
Day 43
Day 71
No Steroids
Steroids ≤ 15mg/Day
Steroids ≥ 20mg/Day
Previous antiTNF
Change in UC Conmeds
= Dosing Day

FIG. 3E



Simulated Serum rHuMAb Beta7 Concentration (µg/mL)
100
10
1
0.1
0
14
28
42
56
70
84
98
112
126
140
Time (Day)
100 mg wk 0, 4, 8
420 mg wk 0 + 300 mg x 3 (wks 2, 4, 8)

FIG. 4



Cmax
Cmax After Last Dose (µg/mL)
200
180
160
140
120
100
80
60
40
20
Flat Dose
Body-weight
AUC
AUC0-84 (day*µg/mL)
5000
4000
3000
2000
1000
0
Flat Dose
Body-weight

FIG. 5



Kabat# 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
HVR1
huKI D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q S I S N Y L A W
Fib504 D V V M T Q S P A T L S V T P G E R I S L S C R A S E S V D T Y L H W
504K graft D I Q M T Q S P S S L S A S V G D R V T I T C R A S E S V D T Y L H W
hu504-5 S L
hu504-16 L
hu504-32 D L
Kabat# 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
HVR2
huKI Y Q Q K P G K A P K L L I Y A A S S L E S G V P S R F S G S G S G T D F T L T I
Fib504 Y Q Q K P N E S P R L L I K Y A S Q S I S G I P S R F S G S G S G T D F T L S I
504K graft Y Q Q K P G K A P K L L I K Y A S Q S I S G V P S R F S G S G S G T D F T L T I
Kabat# 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 a 96 97 98 99 100 101 102 103 104 105 106 107 108
HVR3
huKI S S L Q P E D F A T Y Y C Q Q Y N S L P W T F G Q G T K V E I K R (SEQ ID NO.:12)
Fib504 N G V E L E D L S I Y Y C Q Q G N S L P N T F G A G T K L E L K R (SEQ ID NO.:10)
504K graft S S L Q P E D F A T Y Y C Q Q G N S L P N T F G Q G T K V E I K R (SEQ ID NO.:14)

FIG. 6A



Kabat# 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42
HVR1
hum III E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y A M S W V R Q A P G
Fib504 E V Q L Q E S G P G L V K P S Q S L S L T C S V T G F F I T N N Y W G W I R K F P G
504K graft E V Q L V E S G G G L V Q P G G S L R L S C A A S G F F I T N N Y W G W V R Q A P G
Kabat# 43 44 45 46 47 48 49 50 51 52 a 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 a
HVR2
hum III K G L E W V S V I S G D G G S T Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N
Fib504 N K M E W M G Y I S Y S G S T S Y N P S L K S R I S I T R D T S K N Q F F L Q L N
504K graft K G L E W V G Y I S Y S G S T S Y N P S L K S R F T I S A D T S K N T A Y L Q M N
hu504-5 R F
hu504-16 R F
hu504-32 R F
Kabat# b c 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 a k 101 102 103 104 105 106 107 108 109 110 111 112 113
HVR3
hum III S L R A E D T A V Y Y C A R G F D Y W G Q G T L V T V S S (SEQ ID NO.:13)
Fib504 S V T T E D T A T Y Y C A M T G S S G Y F D F W G P G T M V T V S S (SEQ ID NO.:11)
504K graft S L R A E D T A V Y Y C A M T G S S G Y F D F W G Q G T L V T V S S (SEQ ID NO.:15)

FIG. 6B



Dosing Visits
Group A: rhuMAb Beta7 100 mg Monthly SC
Group B: rhuMAb Beta7 420 mg Wk 0, 300 mg Wks 2, 4, & 8 SC
Group C: Placebo SC
Steroid Taper
Screening
-5
Week
0
2
4
6
8
10
12
14
16
28
Secondary Endpoint
Primary Endpoint
Safety Follow-up or Open-label Extension Rollover
SC = Subcutaneous
Placebo
Active Treatment

FIG. 7



Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10
Patient 11
Patient 12
Patient 13
Patient 14
Patient 15
Patient 16
Partial MCS
0
1
2
3
4
5
6
7
8
9
Week0
Week4
Week8
Week12
Week16
Study Week

FIG. 8